Guidlines and treatment of osteoporosis

Reading File

Finding Sources

Searching PubMed

"osteoporosis"[MeSH Terms] AND "treatment guidelines"

Searching the Web

osteoporosis treatment guidelines 2024 2025 pharmacological management

Finding Sources

Reading File

Finding Sources

Reading File

Loading Image

Searching Images

osteoporosis treatment algorithm pharmacological management flowchart

I have two excellent management flowchart images. I now have comprehensive content from Harrison's 22E (2025), Goldman-Cecil, web guidelines (NOGG 2024, ACP 2023, AACE), and relevant diagrams to synthesize a thorough answer.

Osteoporosis: Guidelines and Treatment

Definition & Diagnosis

Osteoporosis is a skeletal disorder characterized by compromised bone strength that predisposes to an increased risk of fracture. The WHO defines it as bone mineral density (BMD) T-score ≤ −2.5 standard deviations below young-adult mean. Osteopenia is T-score between −1.1 and −2.4.

Dual-energy X-ray absorptiometry (DXA) at the femoral neck and lumbar spine (L1–L4) is the gold-standard diagnostic tool. T-scores use NHANES reference values for women aged 20–29, applied equally to men.

Risk Assessment: FRAX

FRAX (Fracture Risk Assessment Tool) estimates the 10-year probability of a major osteoporotic fracture (hip, vertebral, forearm, humerus) and is central to all current guidelines.

FRAX Threshold (USA)	Action
10-year major fracture risk >20%	Treat
10-year hip fracture risk >3%	Treat
Low risk	Lifestyle measures, reassess in 2–4 years

Key clinical risk factors entered into FRAX include: age, sex, BMI, prior fragility fracture, parental hip fracture, glucocorticoid use, rheumatoid arthritis, secondary osteoporosis, smoking, and alcohol intake (≥3 units/day).

Indications for DXA Scanning

Women ≥65 years and men ≥70 years (routine screening)
Postmenopausal women and men ≥50 with clinical risk factors
Individuals on long-term glucocorticoids (≥3 months)
Any fragility fracture after age 50
Vertebral imaging in women ≥70 or men ≥80 if T-score <−1.0

Non-Pharmacological Management (All Patients)

These apply universally across all risk categories:

Calcium: 1,000 mg/day (age 19–50); 1,200 mg/day (women >51, men >70) — dietary preferred, supplement if deficient
Vitamin D: 800–1,000 IU/day (target serum 25(OH)D >50 nmol/L); up to 2,000 IU/day in deficient patients
Weight-bearing and resistance exercise (reduces fall risk and improves bone density)
Fall prevention: balance training, home hazard assessment, vision correction
Smoking cessation and alcohol reduction (<2 units/day)
Avoid immobility and optimize nutrition (adequate protein)

Pharmacological Treatment

Overview

Pharmacologic therapies are classified as antiresorptive or anabolic:

Class	Agents
Antiresorptive	Bisphosphonates, Denosumab, SERMs (Raloxifene, Bazedoxifene), Estrogen therapy, Calcitonin
Anabolic	Teriparatide, Abaloparatide, Romosozumab (dual action)

1. Bisphosphonates — First-Line Therapy

The 2023 American College of Physicians (ACP) guidelines reinforce bisphosphonates as the clear first-line treatment for postmenopausal women and men with osteoporosis (updated from earlier guidance that had treated denosumab as equivalent).

Agent	Route	Dose	Frequency
Alendronate	Oral	70 mg	Weekly
Risedronate	Oral	35 mg or 150 mg	Weekly or monthly
Ibandronate	Oral / IV	150 mg PO; 3 mg IV	Monthly / every 3 months
Zoledronic acid	IV	5 mg	Annually

Mechanism: Bind hydroxyapatite, inhibit osteoclast farnesyl pyrophosphate synthase → reduced bone resorption.

Fracture reduction:

Vertebral fractures: ~50–70% relative risk reduction
Hip fractures: ~40% (alendronate, zoledronic acid)
Non-vertebral fractures: ~20–40%

Duration (NOGG 2024):

Oral bisphosphonates: at least 5 years, then reassess
IV bisphosphonates (zoledronate): at least 3 years, then reassess
Extended therapy (beyond 5 years oral / 3 years IV) for: age ≥70, prior hip/vertebral fracture, high-dose glucocorticoids (≥7.5 mg prednisolone/day)

Drug holiday: After 5 years oral or 3 years IV in lower-risk patients, a temporary pause of 18–36 months can be considered, with reassessment.

Side effects:

GI irritation (oral); esophageal ulceration if not taken properly
Acute-phase reaction (flu-like) with first IV dose
Rare: osteonecrosis of the jaw (ONJ), atypical femoral fractures (with prolonged use >5 years)

Contraindications: eGFR <35 mL/min (most bisphosphonates), esophageal dysmotility (oral forms), hypocalcemia.

2. Denosumab (Prolia) — Second-Line / High-Risk

Mechanism: Fully humanized monoclonal antibody against RANKL → inhibits osteoclastogenesis → ↓ bone resorption while allowing continued bone formation.

Dose: 60 mg SC every 6 months

Approved for: Postmenopausal osteoporosis, male osteoporosis, glucocorticoid-induced osteoporosis, and oncology (bone loss from hormonal therapies in breast/prostate cancer).

Advantages: Usable in renal impairment (unlike bisphosphonates); larger BMD gains than bisphosphonates; no fixed treatment duration.

Critical warnings:

Do NOT stop denosumab abruptly — rebound increase in bone turnover occurs, leading to multiple vertebral fractures. Always transition to a bisphosphonate when stopping (NOGG 2024 recommendation #19).
Before starting, ensure a long-term plan is in place.
Risk of hypocalcemia, especially in patients with low GFR.

3. Anabolic Agents — For Very High-Risk Patients

Used when fracture risk is very high (T-score ≤ −3.0, multiple prior fractures, or failure of antiresorptives).

Teriparatide (PTH 1-34)

Dose: 20 µg SC daily for up to 24 months
Stimulates osteoblast activity → new bone formation
Reduces vertebral fractures by ~65%, non-vertebral ~35%
Must be followed by antiresorptive therapy to maintain gains

Abaloparatide (PTHrP analogue)

Dose: 80 µg SC daily for up to 18 months
Similar mechanism to teriparatide; may have a more cortical bone effect
Followed by antiresorptive consolidation therapy

Romosozumab (Evenity) — Dual Action

Mechanism: Anti-sclerostin monoclonal antibody → simultaneously stimulates bone formation AND inhibits resorption (dual action)
Dose: 210 mg SC monthly for 12 months only
Produces the largest 12-month BMD gains of any agent
Followed by antiresorptive therapy (denosumab or bisphosphonate)
Contraindicated in patients with prior MI or stroke within 12 months (cardiovascular signal)

4. Selective Estrogen Receptor Modulators (SERMs)

Agent	Notes
Raloxifene	60 mg/day; reduces vertebral fractures ~40%; no hip fracture benefit; used in women <60 or <10 years post-menopause without vasomotor symptoms; ↑ VTE risk
Bazedoxifene	Combined with conjugated estrogens (Duavee); bone protection + treats vasomotor symptoms

5. Hormone Therapy (HT/MHT)

Estrogen ± progestin reduces hip and spine fractures by 34% and all clinical fractures by 24% (Women's Health Initiative)
Now used primarily in women <60 years or <10 years post-menopause with vasomotor symptoms where bone protection is an additional benefit
Not recommended as first-line for osteoporosis treatment alone due to breast cancer, cardiovascular, and VTE risks
Standard doses: conjugated equine estrogen 0.625 mg/day (oral) or estradiol 50 µg/day (transdermal)

6. Calcitonin

Salmon calcitonin 200 IU nasal spray daily
Modest antifracture benefit (vertebral only); analgesic benefit in acute vertebral fracture
Now rarely used as a primary agent; largely superseded

Sequential / Combination Therapy Strategy

Current guidelines recommend a "treat-to-target" sequential approach for high and very high-risk patients:

Very high risk: Start with anabolic agent (teriparatide/abaloparatide/romosozumab) first → follow with antiresorptive (bisphosphonate or denosumab) to consolidate gains
High risk: Bisphosphonate or denosumab first-line; switch to anabolic if inadequate response
Moderate risk: Oral bisphosphonate; consider drug holiday after 5 years

Osteoporosis Management Flowchart for Postmenopausal Women

Osteoporosis Risk Assessment and Management Algorithm

Special Populations

Glucocorticoid-Induced Osteoporosis (GIOP)

Affects all patients on systemic glucocorticoids ≥7.5 mg prednisolone/day for ≥3 months
Begin calcium and vitamin D supplementation for all
Start bisphosphonate (alendronate or risedronate oral; zoledronate IV) based on FRAX-adjusted risk
Denosumab and teriparatide are alternatives
Glucocorticoids cause rapid bone loss — early intervention is key

Male Osteoporosis

First-line: Oral bisphosphonates (alendronate or risedronate) — 2024 IOF/NOS guideline
Second-line: Denosumab or zoledronate
Very high risk: Sequential anabolic followed by antiresorptive
Check testosterone, calcium, 25(OH)D, 24-hour urine calcium to rule out secondary causes

Renal Impairment

Bisphosphonates generally avoid if eGFR <35 mL/min
Denosumab is the preferred antiresorptive in CKD; monitor closely for hypocalcemia
Teriparatide can be used

Monitoring

Marker	Purpose	Timing
BMD (DXA)	Assess treatment response	1–2 years after starting therapy
CTX-I (bone resorption)	Monitor antiresorptive adherence/response	Baseline; 3 months after starting
P1NP (bone formation)	Monitor anabolic agent response	Baseline; 1, 3, 6, 12 months
Serum calcium, vitamin D	Safety monitoring	Periodically

For antiresorptive agents, a >56% decrease in CTX-I or >38% decrease in P1NP at 3 months defines treatment response.

Key Guideline Recommendations Summary

Guideline	Key Points
ACP 2023	Bisphosphonates are clear first-line for postmenopausal osteoporosis (de-emphasized denosumab equivalence)
NOGG 2024 (UK)	Oral bisphosphonates ≥5 years; IV ≥3 years; no abrupt denosumab discontinuation; FRAX-based thresholds
AACE 2020	Risk-stratified approach; anabolics first for very high-risk; sequential therapy
IOF/NOS 2024 (Men)	Alendronate/risedronate first-line; denosumab/zoledronate second-line; anabolics for very high-risk men
Korean Society of Menopause 2024	Treatment response monitoring with BTMs at 3 months; calcium 1,200 mg/day for women >51

Sources: Harrison's Principles of Internal Medicine, 22nd Ed. (2025); Goldman-Cecil Medicine, International Ed.; Lippincott Pharmacology; Rockwood & Green's Fractures in Adults, 10th Ed. (2025); NOGG 2024 Guidelines; ACP 2023; IOF/NOS Men Guidelines 2024. PubMed: PMID 40652262 (network meta-analysis of antiresorptive/anabolic agents, 2025).

This is a shared conversation. Sign in to Orris to start your own chat.